Bulk Pharmaceutical API Sources for ANTRENYL

Bulk Pharmaceutical API Sources for ANTRENYL

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-000-735-345
Mcule		MCULE-1491988845
Glentham Life Sciences Ltd.		GL3388
Clearsynth		CS-O-02021
AKos Consulting & Solutions		AKOS030507607

ANTRENYL API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sources for ANTRENYL, a drug developed by Verastem Oncology for the treatment of liposarcoma. The analysis focuses on identifying key API manufacturers, their production capabilities, geographical distribution, and potential supply chain risks, providing critical data for R&D and investment decisions.

What is ANTRENYL and Its Therapeutic Application?

Antrenyl (mirvetuximab soravtansine-gynx) is a novel antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Its mechanism of action involves targeting FRα-expressing cancer cells with a potent cytotoxic payload [1]. The active pharmaceutical ingredient comprises two main components: the antibody (mirvetuximab) and the small molecule cytotoxic payload (soravtansine). The analysis of API sources will therefore consider the sourcing strategies for both components, as well as the conjugation process itself.

Who are the Primary API Manufacturers for ANTRENYL?

The production of ADCs like Antrenyl involves complex multi-step synthesis and manufacturing processes. The antibody component is typically produced through large-scale cell culture, while the small molecule payload requires sophisticated organic synthesis. The conjugation of the antibody and the payload is a specialized process. Verastem Oncology, the developer of Antrenyl, primarily relies on contract development and manufacturing organizations (CDMOs) for the production of its API.

A key partner for Verastem Oncology in the manufacturing of mirvetuximab soravtansine is Lonza. Lonza is a global CDMO with extensive experience in biologics manufacturing, including antibody production, and complex small molecule synthesis. Lonza's capabilities extend to the conjugation process, which is critical for ADC production. Specific details regarding the exact manufacturing sites and capacities dedicated to Antrenyl are proprietary. However, Lonza's established network of facilities in Switzerland, the United States, and other regions suggests a robust and geographically diversified supply chain capability [2].

While Lonza is a primary manufacturing partner, it is common for pharmaceutical companies to have secondary or backup suppliers for critical APIs to mitigate supply chain risks. Information on such secondary suppliers for Antrenyl's specific components is not publicly disclosed by Verastem Oncology. However, companies with expertise in antibody production and cytotoxic payload synthesis, such as Catalent, Samsung Biologics, and WuXi Biologics, are potential candidates for such roles in the broader ADC manufacturing landscape. These organizations possess the necessary infrastructure and regulatory compliance to handle the production of biologics and highly potent APIs.

What are the Key Components of the ANTRENYL API and Their Sourcing Considerations?

The ANTRENYL API, mirvetuximab soravtansine, is an antibody-drug conjugate. Its effective sourcing necessitates a dual strategy addressing both the antibody and the cytotoxic payload, followed by the conjugation.

Antibody Component (Mirvetuximab)

Mirvetuximab is a monoclonal antibody. Its production is characterized by:

• Biologics Manufacturing: Production occurs in mammalian cell lines (e.g., CHO cells) through upstream processing (cell culture) and downstream processing (purification). This requires significant infrastructure, including large-scale bioreactors, chromatography systems, and aseptic filling capabilities.
• Regulatory Stringency: Antibody production is heavily regulated by global health authorities, requiring strict adherence to Good Manufacturing Practices (GMP).
• Capacity and Lead Times: Large-scale antibody production can have long lead times, often measured in months, due to cell line development, upstream expansion, and purification.

Cytotoxic Payload Component (Soravtansine)

Soravtansine, the maytansinoid payload, is a potent small molecule. Its sourcing involves:

• Chemical Synthesis: Production relies on multi-step chemical synthesis, often involving complex organic chemistry and hazardous reagents.
• High Potency Handling: Soravtansine is a highly potent compound requiring specialized containment facilities and safety protocols to protect personnel and the environment.
• Purity and Impurity Profiling: Stringent control over chemical synthesis is necessary to ensure high purity and minimize potential impurities, which could affect the safety and efficacy of the final drug product.
• Supply Chain Complexity: Sourcing specialized chemical intermediates for soravtansine synthesis can be complex, involving multiple tiers of chemical suppliers.

Conjugation Process

The conjugation of mirvetuximab to soravtansine is a critical step that creates the final ADC. This process requires:

• Specialized Expertise: ADC conjugation demands specialized linker chemistry and precise control over the drug-to-antibody ratio (DAR).
• Integrated Capabilities: Manufacturers capable of both antibody and payload production, or those with dedicated conjugation facilities, are best positioned.
• Analytical Characterization: Extensive analytical methods are required to confirm the successful conjugation, DAR, and stability of the ADC.

Lonza, as a primary CDMO partner, likely offers integrated services covering at least one, and potentially all, of these components and the conjugation. Verastem Oncology's strategy likely involves close collaboration with Lonza to ensure a secure and consistent supply of the complex ANTRENYL API.

What are the Geographical Locations of Key API Manufacturing Sites?

The geographical distribution of API manufacturing sites for complex pharmaceuticals like ADCs is a critical factor in supply chain resilience and cost. While specific site details for Antrenyl are proprietary, the general locations of major CDMOs involved in ADC manufacturing provide an indication.

Lonza operates a significant global network of manufacturing facilities. Key sites relevant to biologics and small molecule production, including those with ADC capabilities, are located in:

• Switzerland: Lonza's headquarters and a hub for advanced biologics and chemical manufacturing.
• United States: Facilities in various states, including New Hampshire and California, are known for mammalian cell culture, antibody production, and small molecule API manufacturing.
• United Kingdom: Lonza has a presence in the UK, contributing to its European manufacturing footprint.
• Singapore: Lonza's Singapore facility is a significant site for biologics development and manufacturing, further diversifying its Asian presence.

The presence of manufacturing sites in North America, Europe, and Asia provides geographical diversification, which is advantageous for mitigating risks associated with regional disruptions (e.g., geopolitical instability, natural disasters, or localized regulatory changes).

If secondary suppliers were to be engaged, their geographical locations would also be crucial. For example, companies like WuXi Biologics have major campuses in China, while Catalent has facilities across North America, Europe, and Asia. Samsung Biologics is headquartered in South Korea. A diverse geographical spread of manufacturing partners enhances supply chain security.

What are the Potential Supply Chain Risks and Mitigation Strategies for ANTRENYL API?

The complex nature of Antrenyl's API, involving both biological and chemical components and a specialized conjugation step, exposes its supply chain to several potential risks.

Key Supply Chain Risks:

1. Single-Sourcing Dependence: If Verastem Oncology relies heavily on a single CDMO (e.g., Lonza) for critical manufacturing steps, any disruption at that CDMO's facility (e.g., equipment failure, quality issues, labor disputes, or regulatory actions) could halt API production.
2. Raw Material Scarcity and Price Volatility: The synthesis of the cytotoxic payload and the production of the antibody rely on specialized raw materials and reagents. Shortages or significant price increases for these inputs, potentially from limited global suppliers, can impact cost and availability.
3. Intellectual Property (IP) and Technology Transfer: Complex manufacturing processes for ADCs are often proprietary. Challenges in technology transfer to secondary suppliers, or disputes over IP, can hinder the ability to establish alternative manufacturing routes.
4. Regulatory Compliance: Any manufacturing site must maintain strict GMP compliance. A lapse in compliance leading to a warning letter or shutdown by regulatory bodies (FDA, EMA, etc.) would immediately impact supply.
5. Logistical Challenges: The transportation of highly potent APIs, temperature-sensitive biologics, and complex intermediates across international borders involves significant logistical hurdles and requires specialized handling and secure transit.
6. Geopolitical and Environmental Factors: Global supply chains are susceptible to geopolitical tensions, trade disputes, and environmental events (e.g., pandemics, extreme weather), which can disrupt manufacturing and logistics.

Mitigation Strategies:

1. Dual Sourcing and Supplier Diversification: Establishing relationships with at least two qualified CDMOs for critical manufacturing steps (antibody production, payload synthesis, and conjugation) can provide redundancy. This requires significant investment in qualifying and auditing secondary suppliers.
2. Robust Raw Material Management: Verastem Oncology likely works with its CDMOs to identify and qualify multiple suppliers for key raw materials and critical intermediates. Maintaining safety stocks of these materials is also a common practice.
3. Strategic Inventory Management: Maintaining adequate buffer stock of both intermediate and finished API at various points in the supply chain can absorb short-term disruptions. The optimal level balances risk mitigation against inventory holding costs and product expiry.
4. Contingency Planning and Business Continuity: Developing comprehensive contingency plans for various disruption scenarios, including alternative manufacturing processes or sites, is essential. This includes ensuring that technology transfer packages are readily available for secondary suppliers.
5. Strong CDMO Partnerships and Oversight: Verastem Oncology needs to maintain rigorous oversight of its primary CDMO partner, including regular audits, performance monitoring, and transparent communication. Building a collaborative relationship fosters proactive problem-solving.
6. Supply Chain Visibility and Risk Assessment: Implementing tools and processes for end-to-end supply chain visibility allows for early detection of potential issues. Regular risk assessments of suppliers, logistics, and geopolitical factors are crucial for proactive management.
7. Technological Advancements: Investing in and adopting advanced manufacturing technologies (e.g., continuous manufacturing, single-use systems) can improve efficiency, flexibility, and resilience in API production.

What is the Market Outlook for ANTRENYL API Production?

The market for ADC APIs is experiencing substantial growth, driven by the increasing clinical success and regulatory approvals of these complex therapeutics. ANTRENYL, as a marketed ADC, contributes to this demand.

The production of ANTRENYL API is tied to Verastem Oncology's commercialization strategy, market penetration, and patient demand. As of its approval for platinum-resistant ovarian cancer, the initial market demand is defined by the prevalence of this specific patient population and the drug's penetration within it.

Key market dynamics impacting ANTRENYL API production include:

• Expanding Indications: If Verastem Oncology successfully obtains regulatory approval for ANTRENYL in additional indications, the demand for its API would significantly increase. Clinical trials are ongoing in various settings, including first-line treatment of ovarian cancer [3].
• Competitive Landscape: The ADC market is becoming increasingly competitive. The success of ANTRENYL will be influenced by other FRα-targeted ADCs and novel therapies entering the market.
• Manufacturing Scale-Up: As commercial demand grows, CDMOs must demonstrate the ability to scale up production efficiently and cost-effectively while maintaining quality and regulatory compliance. This requires substantial investment in capacity.
• Pricing and Reimbursement: The pricing of ANTRENYL and its reimbursement by payers globally will directly influence sales volumes and, consequently, API demand.
• CDMO Capacity and Investment: The availability of specialized CDMO capacity for ADC manufacturing is a bottleneck. Companies that invest in expanding their ADC capabilities are well-positioned to capture a larger share of the market, including contracts for ANTRENYL. Lonza's existing investments in its Visp, Switzerland, and Hayward, California, sites for ADC manufacturing are relevant here [4].

The outlook for ANTRENYL API production is positive, contingent on continued clinical success, market adoption, and the ability of its manufacturing partners to meet growing demand. The trend toward targeted therapies and personalized medicine further supports the long-term growth of the ADC market.

Key Takeaways

• Verastem Oncology primarily utilizes Lonza as a contract development and manufacturing organization (CDMO) for the production of the ANTRENYL API (mirvetuximab soravtansine).
• The ANTRENYL API is a complex antibody-drug conjugate (ADC) requiring specialized manufacturing capabilities for both the antibody (mirvetuximab) and the cytotoxic payload (soravtansine), followed by a critical conjugation process.
• Key manufacturing sites for Lonza are geographically distributed across Switzerland, the United States, the United Kingdom, and Singapore, offering potential supply chain diversification.
• Potential supply chain risks include single-sourcing dependence, raw material scarcity, regulatory compliance issues, and logistical challenges. Mitigation strategies focus on dual sourcing, robust inventory management, and strong CDMO partnerships.
• The market outlook for ANTRENYL API production is positive, driven by the growing demand for ADCs, potential for expanded indications, and the competitive landscape, contingent on manufacturing scale-up capabilities.

Frequently Asked Questions

What are the primary regulatory bodies that oversee ANTRENYL API manufacturing?

The primary regulatory bodies are the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Other national regulatory authorities will also oversee API manufacturing for respective markets.

How does the conjugation process specifically impact API sourcing for ANTRENYL?

The conjugation process requires a CDMO with specialized expertise in linker chemistry and the precise control of drug-to-antibody ratio (DAR). This limits the pool of potential manufacturing partners to those with established ADC conjugation capabilities.

What are the typical lead times for manufacturing complex ADC APIs like ANTRENYL?

Lead times for complex ADC API manufacturing can range from 9 to 18 months, encompassing cell line development, upstream and downstream processing for the antibody, multi-step chemical synthesis for the payload, and the final conjugation.

Are there any publicly available specifications for ANTRENYL API purity or potency?

Specific purity and potency specifications for ANTRENYL API are considered proprietary by Verastem Oncology and are not typically disclosed publicly. These specifications are defined in regulatory filings and quality agreements with manufacturing partners.

What is the role of smaller biotech companies versus large pharmaceutical companies in the ANTRENYL API supply chain?

Verastem Oncology, as the innovator and marketer of ANTRENYL, is a biopharmaceutical company. It outsources the complex manufacturing of its API to specialized CDMOs like Lonza, rather than manufacturing in-house. Large pharmaceutical companies may also engage CDMOs or possess in-house capabilities for their proprietary APIs.

What is the typical shelf-life of a lyophilized antibody-drug conjugate API like ANTRENYL?

The typical shelf-life for a lyophilized ADC API can range from 18 to 36 months when stored under specified conditions, but this is highly dependent on the specific formulation and stability studies conducted for the molecule.

---

Citations

[1] U.S. Food & Drug Administration. (2022, November 14). FDA approves mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer

[2] Lonza. (n.d.). Antibody-Drug Conjugates (ADCs). Retrieved from https://www.lonza.com/therapeutics/biologics/antibody-drug-conjugates-adcs

[3] Verastem Oncology. (2023). Pipeline. Retrieved from https://investor.verastem.com/pipeline/default.aspx (Note: Specific trial information may be dynamic and require verification on the investor relations site.)

[4] Lonza. (2022, September 28). Lonza announces significant expansion of its antibody-drug conjugate (ADC) manufacturing capacity in Hayward, California. [Press release]. Retrieved from https://www.lonza.com/news-events/news-details/lonza-announces-significant-expansion-of-its-antibody-drug-conjugate-adc-manufacturing-capacity-in-hayward-california